Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter March 19, 2010

Interpretation of serum parathyroid hormone concentrations in dialysis patients: what do the KDIGO guidelines change for the clinical laboratory?

Jean-Claude Souberbielle, Etienne Cavalier and Guillaume Jean


The Kidney Disease: Improving Global Outcomes (KDIGO) have recently replaced the K/DOQI guidelines to help nephrologists in diagnosing, treating and monitoring chronic kidney disease mineral and bone disorders (CKD-MBD). Here, we comment on the KDIGO recommendations concerning the interpretation of parathyroid hormone (PTH) concentrations in dialysis patients: “In patients with CKD stage 5D, we suggest maintaining iPTH in the range of approximately two to nine times the upper normal limit of the assay. We suggest that marked changes in PTH concentrations in either direction within this range prompt an initiation or change in therapy to avoid progression to concentrations outside of this range”. Our comments concern the interpretation of PTH in dialysis patients, but also the more global problem of establishing normal values for PTH.

Clin Chem Lab Med 2010;48:769–74.

Corresponding author: Jean-Claude Souberbielle, Laboratoire d'Explorations Fonctionnelles, Hôpital Necker-Enfants Malades, 149 rue de Sèvres, 75015, Paris, France and Université Paris Descartes, INSERM U845, Paris, France

Received: 2009-12-14
Accepted: 2010-1-21
Published Online: 2010-03-19
Published in Print: 2010-06-01

©2010 by Walter de Gruyter Berlin New York

Scroll Up Arrow